Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation. Transplant BRaVE NH

Phase 2

Recruiting

Conditions: aggressive B-cell lymphoma
10025320
Diffuse large B-cell lymphoma

Registration Number: NL-OMON46902

Lead Sponsor: HOVO

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 25

Inclusion Criteria

• CD30 positive DLBCL, i.e. more than 1% of DLBCL cells CD30 positive according to the WHO classification 2008:.
- CD30 positive DLBCL, including EBV positive DLBCL
- CD30 positive primary mediastinal B-cell lymphoma
• Primary refractory to or in first relapse after first line therapy with R-CHOP or R-CHOP-like therapy
• Age >= 18 years (upper age limit for ASCT at the discretion of the participating center)
• Measurable disease: on CT scan at least 1 lesion/node with a long axis of > 1.5 cm and at least one positive lesion on 18F-FDG PET scan
• WHO performance status 0-2
• Adequate hepatic function:
• Adequate renal function:
• Adequate bone marrow function:
• Hemoglobin must be >= 8 g/dL (5.0 mmol/L), transfusion is allowed
• Eligible for high-dose chemotherapy and ASCT
• Resolution of relevant toxicities from first-line therapy
• Life expectancy of > 3 months with treatment
• Negative pregnancy test at study entry, if applicable
• Female patient is either post-menopausal for at least 1 year before screening visit or surgically sterile or if of childbearing potential, agrees to practice 2 effective methods of contraception, at the same time, or agrees to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months after the last dose of study drug
• Male patients, even if surgically sterilized, (i.e. status post vasectomy) agree to practice effective barrier contraception, or agrees to completely abstain from heterosexual intercourse, during the entire study period and through 12 months after the last dose of study drug
• Written informed consent
• Patient is capable of giving informed consent

Exclusion Criteria

• Peripheral sensory or motor neuropathy grade >= 2
• Known cerebral or meningeal disease (NHL or any other etiology), including signs and symptoms of progressive multifocal leukoencephalopathy (PML)
• Symptomatic neurological disease compromising normal activities of daily living or requiring medications
• Transformed lymphoma
• DLBCL after organ transplantation
• Immunodeficiency-associated B-cell lymphoproliferative disease
• Use of other investigational agents within at least 5 half-lives of the most recent agent used prior to study entry
• Treatment with myelosuppressive chemotherapy or biological therapy <= 4 weeks before study entry
• Female patients who are breast feeding
• History of another malignancy less than 3 years before study inclusion, or previously diagnosed with another malignancy and have evidence of residual disease, with the exception of non-melanoma skin cancer, completely resected melanoma TNMpT1 and carcinoma in situ of the uterine cervix
• Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin
• Active hepatitis B or C infection
• HIV positivity
• Radiation therapy within 8 weeks prior to start of protocol treatment. Emergency radiation therapy is allowed, as long as measurable disease (at non-irradiated sites) persists
• Patients with a serious psychiatric disorder that could, in the investigator's opinion, potentially interfere with the completion of treatment according to protocol
• Major organ dysfunction, unless NHL-related
• Patients who have any severe and/or uncontrolled medical condition or other conditions that could affect their participation in the study
• Thyroid abnormalities when thyroid function cannot be maintained in the normal range by medication
• Current participation in another clinical trial interfering with this trial
• Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• Claustrophobia to the extent that PET-CT is impossible

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Phase 1 part<br /><br>Primary endpoint<br /><br>• The rate of patients with serious toxicity during cycle 1-2 of the<br /><br>combination BV-R-DHAP<br /><br><br /><br>Phase 2 part<br /><br>Primary efficacy endpoint<br /><br>• Metabolic CR rate (PET-CT) after the third cycle of BV-R-DHAP salvage therapy<br /><br><br /><br>Primary feasibility/toxicity endpoints<br /><br>• Rate of grade 3/4 non-hematological toxicity, including neurotoxicity after<br /><br>each cycle of BV-R-DHAP</p><br>

Secondary Outcome Measures